Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).


Clinical Trial Description

The A4 study is a clinical trial for older individuals who have evidence of amyloid plaque build-up in their brains who may be at risk for memory loss and cognitive decline due to Alzheimer's disease. The A4 study will test an anti-amyloid investigational drug in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia with the aim of slowing memory and cognitive decline. The A4 study will also test whether anti-amyloid treatment can delay the progression of AD related brain injury on imaging and other biomarkers. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02008357
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 3
Start date February 28, 2014
Completion date June 8, 2023

See also
  Status Clinical Trial Phase
Completed NCT02488720 - Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Recruiting NCT03544801 - Renji Cerebral Small Vessel Disease Corhort Study
Recruiting NCT02813434 - Cerebral Amyloid Imaging Using Florbetapir (AV-45) Phase 3
Completed NCT00400790 - Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane N/A
Completed NCT00052091 - Therapy for Depressed Elders With Thought Problems Phase 3
Completed NCT00021866 - Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy N/A
Completed NCT00267163 - Brain Imaging and Mental Disorders of Aging Intervention Phase 4
Not yet recruiting NCT04079075 - Multiple Interventions to Prevent Cognitive Decline N/A
Terminated NCT03696082 - A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines N/A
Completed NCT02918539 - Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Active, not recruiting NCT01708837 - Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction Phase 4
Completed NCT01290939 - Bevacizumab and Lomustine for Recurrent GBM Phase 3
Terminated NCT00548327 - The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype Phase 2
Unknown status NCT00256425 - Cognitive Rehabilitation of Glioma Patients Phase 3
Recruiting NCT03926351 - High Dose Omega 3 in People at Risk for Dementia Phase 2
Completed NCT02118571 - Schizophrenia Cognition Scale Development N/A
Completed NCT01481961 - Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease N/A
Completed NCT00788918 - Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) N/A
Completed NCT00564902 - The Zeaxanthin and Visual Function Study N/A
Completed NCT00529581 - A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis Phase 2